Participation of the nucleus accumbens dopaminergic system in the antidepressant-like actions of a diet rich in omega-3 polyunsaturated fatty acids.
Animals
Antidepressive Agents
/ chemistry
Behavior, Animal
/ drug effects
Biogenic Monoamines
/ analysis
Diet
Dopamine
/ metabolism
Dopamine Antagonists
/ pharmacology
Fatty Acids, Omega-3
/ chemistry
Female
Male
Maze Learning
/ drug effects
Mice
Mice, Inbred C57BL
Nucleus Accumbens
/ drug effects
Receptors, Dopamine D2
/ metabolism
Tyrosine 3-Monooxygenase
/ metabolism
Ventral Tegmental Area
/ enzymology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
12
2019
accepted:
04
03
2020
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
1
7
2020
Statut:
epublish
Résumé
The beneficial effects of omega (ω)-3 polyunsaturated fatty acid (PUFA) supplementation on major depressive disorder have been actively studied, but the underlying mechanism remains unknown. The present study examined the involvement of the nucleus accumbens (NAc) dopaminergic systems in behavioral changes in mice fed a diet high in ω-3 PUFAs. Mice fed a diet containing about double the amount of ω-3 PUFAs (krill oil (KO) diet) exerted shorter immobility times in the forced swim test (FST) than mice fed a control diet, containing only α-linolenic acid (ALA) as ω-3 PUFAs. The shorter immobility times were observed in both male and female mice. A dopamine metabolite, 3,4-dihydroxyphenylacetic acid, increased in the NAc in male mice fed the KO diet when compared with those fed the control diet. In addition, dopamine, 3-methoxytyramine, and homovanillic acid increased in the NAc in female mice fed the KO diet. Notably, the effects of the KO diet on the immobility time in the FST were abolished by microinjection of sulpiride, an antagonist of D2-like receptors, into the NAc. A similar microinjection of an antagonist selective for D1-like receptors, SKF83566, also abolished the reduction in immobility in the FST. Moreover, we found that tyrosine hydroxylase-positive cells increased in the ventral tegmental area (VTA) in mice fed the KO diet. These results suggest that modulation of the VTA-NAc dopaminergic pathway is one of the mechanisms by which a KO diet rich in ω-3 PUFAs reduces the immobility behavior in the mouse FST.
Identifiants
pubmed: 32210469
doi: 10.1371/journal.pone.0230647
pii: PONE-D-19-34228
pmc: PMC7094879
doi:
Substances chimiques
Antidepressive Agents
0
Biogenic Monoamines
0
Dopamine Antagonists
0
Fatty Acids, Omega-3
0
Receptors, Dopamine D2
0
Tyrosine 3-Monooxygenase
EC 1.14.16.2
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230647Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Front Behav Neurosci. 2016 Aug 23;10:164
pubmed: 27601985
Brain Res. 2008 May 7;1208:160-9
pubmed: 18381208
Biochim Biophys Acta. 2001 Jun 29;1532(3):203-12
pubmed: 11470241
Psychiatry Clin Neurosci. 2016 Jun;70(6):253-4
pubmed: 27004997
J Neurosci. 2011 Sep 7;31(36):12866-79
pubmed: 21900565
J Lipid Res. 2000 Jan;41(1):32-40
pubmed: 10627499
Nature. 1977 Apr 21;266(5604):730-2
pubmed: 559941
J Neurochem. 2008 Jul;106(2):662-71
pubmed: 18410511
Behav Brain Res. 2015 Sep 1;290:17-31
pubmed: 25907747
Nutrients. 2015 May 07;7(5):3300-21
pubmed: 25961320
Neurosci Res. 2019 Aug 22;:
pubmed: 31445058
Am J Clin Nutr. 1995 Jul;62(1):1-9
pubmed: 7598049
Neuropsychopharmacology. 2013 Jul;38(8):1409-25
pubmed: 23389689
Neurochem Int. 2011 Feb;58(3):321-9
pubmed: 21184792
Biol Psychiatry. 2011 Apr 15;69(8):788-94
pubmed: 21334601
Br J Nutr. 2013 Jun;109(11):2059-66
pubmed: 23051591
Transl Psychiatry. 2016 Mar 15;6:e756
pubmed: 26978738
Prostaglandins Leukot Essent Fatty Acids. 1998 Aug;59(2):127-35
pubmed: 9774176
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1085-93
pubmed: 20677367
Psychoneuroendocrinology. 2009 Feb;34(2):199-211
pubmed: 18848400
Neuropsychopharmacology. 2014 Jul;39(8):1852-60
pubmed: 24518289
Am J Clin Nutr. 2002 Apr;75(4):662-7
pubmed: 11916751
J Psychiatr Res. 2008 Jan;42(1):58-63
pubmed: 17070845
J Neurochem. 1996 Apr;66(4):1582-91
pubmed: 8627314
Ann Neurol. 2003;53 Suppl 3:S26-36; discussion S36-8
pubmed: 12666096
Am J Clin Nutr. 2010 Mar;91(3):757-70
pubmed: 20130098
J Nutr Biochem. 2012 Aug;23(8):924-8
pubmed: 21852084
Pharmacol Ther. 2018 Jan;181:108-125
pubmed: 28723414
Front Immunol. 2016 Nov 15;7:486
pubmed: 27895640
Lipids Health Dis. 2013 Jan 25;12:6
pubmed: 23351783
Life Sci. 1996;58(21):1805-16
pubmed: 8637406
Neuropharmacology. 2012 Jan;62(1):184-91
pubmed: 21740919
J Mol Cell Cardiol. 2017 Feb;103:74-92
pubmed: 27986444
Neurochem Int. 2010 Oct;57(3):235-47
pubmed: 20538025
J Vis Exp. 2012 Jan 28;(59):e3769
pubmed: 22315011
Genes Brain Behav. 2004 Oct;3(5):287-302
pubmed: 15344922
Mol Membr Biol. 1995 Jan-Mar;12(1):131-4
pubmed: 7767372
J Clin Psychiatry. 2011 Aug;72(8):1054-62
pubmed: 20584525
Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):383-99
pubmed: 10817922
Int J Neuropsychopharmacol. 2014 Mar;17(3):383-91
pubmed: 24300434
Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84
pubmed: 22865617
Int J Mol Sci. 2017 Nov 28;18(12):
pubmed: 29182579